2026-09-05T22:48:16Zhttps://gredos.usal.es/oai/request

oai:gredos.usal.es:10366/1620022025-04-30T19:32:57Zcom_10366_4001com_10366_3947com_10366_3946com_10366_3823col_10366_4002

Zazo, Hinojal Colino, Clara I Warzecha, Klaudia T Hoss, Mareike Gbureck, Uwe Trautwein, Christian Tacke, Frank Lanao, José M Bartneck, Matthias HIV; drug delivery; gold nanoparticles; macrophages; nanocarriers; stavudine. The human immunodeficiency virus (HIV) continues to be a global pandemic and there is an urgent need for innovative treatment. Immune cells represent a major target of virus infection, but are also therapeutic targets. Currently, no antiretroviral therapy targets macrophages, which function as portal of entry and as major long-term deposit of HIV. It has been shown before that human macrophages efficiently internalize gold nanoparticles, a fact which might be used to target them with drug-nanoparticle conjugates. Here, the authors use gold nanocarriers to facilitate delivery of stavudine, a widely used antiretroviral drug, to primary human macrophages. Using an ease-of-use coupling method, a striking potentiation of stavudine intake by macrophages using gold nanocarriers is shown. Further, the carriers induce a specific subtype of proinflammatory activation indicative for antiviral activity of macrophages, which suggests promising novel treatment options for HIV. 2025-01-20 2025-01-20 2017-03 info:eu-repo/semantics/article 1616-5187 http://hdl.handle.net/10366/162002 10.1002/mabi.201600359 27748547 1616-5195 eng http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Attribution-NonCommercial-NoDerivatives 4.0 Internacional